Adenoid Cystic Carcinoma cells lines UM-HACC1, UM-HACC2A, and UM-HACC-6 were initially described by Warner et al. (2013) (link). Cells were maintained in a 5% CO2 humidified incubator at 37 °C and cultured in RPMI 1640 (Thermo Scientific, Waltham, MA, USA) supplemented with 10% Fetal Bovine Serum (Thermo Scientific), 1% antibiotic (Invitrogen, Carlsbad, CA, USA), 1% L-glutamine (Invitrogen), 20 ng/ml epidermal growth factor (Sigma–Aldrich, St. Louis, MO, USA), 400 ng/ml hydrocortisone (Sigma–Aldrich), and 5 μg/ml insulin (Sigma–Aldrich). Cells were treated with Vorinostat (SAHA) (Cayman Chemical Company Ann Arbor, MI, USA) and cisplatin (Sigma–Aldrich, St. Louis, MO, USA).
Vorinostat saha
Manufactured by Cayman Chemical
Sourced in United States
Vorinostat (SAHA) is a histone deacetylase (HDAC) inhibitor. It is a white to off-white crystalline powder that is soluble in organic solvents.
Automatically generated - may contain errors
Lab products found in correlation
Fetal bovine serum (fbs), by Thermo Fisher Scientific (4 mentions)
L glutamine, by Thermo Fisher Scientific (2 mentions)
Rpmi 1640, by Thermo Fisher Scientific (2 mentions)
Insulin, by Merck Group (2 mentions)
Cisplatin, by Merck Group (2 mentions)
Hydrocortisone, by Merck Group (2 mentions)
Epidermal growth factor (egf), by Merck Group (2 mentions)
Etoposide, by Cayman Chemical (1 mentions)
Entinostat, by Selleck Chemicals (1 mentions)
Doxorubicin hydrochloride, by Cayman Chemical (1 mentions)
Pcr based detection kit, by Southern Biotech (1 mentions)
Bortezomib, by Santa Cruz Biotechnology (1 mentions)
Epoxomicin, by Santa Cruz Biotechnology (1 mentions)
Nocodazole, by Merck Group (1 mentions)
Valproic acid, by Merck Group (1 mentions)
Entinostat ms 275, by Selleck Chemicals (1 mentions)
Monoclonal anti β actin, by Abcam (1 mentions)
Ta503755, by OriGene (1 mentions)
Mg132, by Merck Group (1 mentions)
Panobinostat lbh589, by Cayman Chemical (1 mentions)
6 protocols using vorinostat saha
1
Adenoid Cystic Carcinoma Cell Lines
2
HDAC Inhibitor Vorinostat Treatment in DSS-Induced Mouse Colitis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
After each week of DSS administration, Ebi3−/− as well as C57BL/6 were treated daily for 5 days with 25 mg/kg body weight Vorinostat (SAHA, Cayman Chemical, Michigan, USA). SAHA was dissolved in 10% DMSO/phosphate-buffered saline. HDAC inhibitor solution and vehicle control were administered intraperitoneally (i.p.).
3
Adenoid Cystic Carcinoma Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Adenoid Cystic Carcinoma cells lines UM-HACC1, UM-HACC2A, and UM-HACC-6 were initially described by Warner et al. (2013) (link). Cells were maintained in a 5% CO2 humidified incubator at 37 °C and cultured in RPMI 1640 (Thermo Scientific, Waltham, MA, USA) supplemented with 10% Fetal Bovine Serum (Thermo Scientific), 1% antibiotic (Invitrogen, Carlsbad, CA, USA), 1% L-glutamine (Invitrogen), 20 ng/ml epidermal growth factor (Sigma–Aldrich, St. Louis, MO, USA), 400 ng/ml hydrocortisone (Sigma–Aldrich), and 5 μg/ml insulin (Sigma–Aldrich). Cells were treated with Vorinostat (SAHA) (Cayman Chemical Company Ann Arbor, MI, USA) and cisplatin (Sigma–Aldrich, St. Louis, MO, USA).
4
Establishing SP-2509 Resistant A673 Cell Line
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A673 cells were sourced from American Type Culture Collection (ATCC) and grown in DMEM with L-Glutamine, 10% Fetal Bovine Serum, 1% Penicillin-Streptomycin-Glutamine, 1% Sodium Pyruvate. Cell culture supernatants were tested yearly for Mycoplasma infection using a PCR based detection kit (Southern Biotech, USA) with cells authenticated by STR profiling (Genetica LabCorp, USA). To generate SP-2509 drug resistant cells, A673 cells were exposed to escalating concentrations of SP-2509 for a period of 7 months (100nM increments). SP-2509 was provided by Dr Sunil Sharma (Huntsman Cancer Institute, Utah), Doxorubicin hydrochloride, Etoposide, Vincristine sulfate, and Vorinostat/SAHA were purchased from Cayman Chemical, and Entinostat was purchased from Selleckchem.
5
Immunoblotting of Cellular UNG Regulation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Primary antibodies: Anti-UNG: Polyclonal PU059 (in-house, 0.5 µg/ml), monoclonal 2C12 (OriGene, Rockville, MD, TA503563, 0.5 µg/ml) and 1G2 (OriGene TA503755, 0.5 µg/ml) (all recognizing catalytic domain of UNG1/2), in-house polyclonal mouse anti-murine UNG. Monoclonal anti-β-actin (Abcam, Cambridge, UK, Ab8226, 0.5 µg/ml), monoclonal anti-PCNA (Santa Cruz Biotechnology, Santa Cruz, CA, sc-56, 0.2 µg/ml), polyclonal anti-p21 (Abcam Ab18209, 0.2 µg/ml), polyclonal anti-acetyllysine (Abcam Ab21623, 0.25 µg/ml). Secondary antibodies according to the manufacturer’s recommendation: Swine anti-rabbit, HRP (Dako, Glostrup, Denmark), rabbit anti-mouse, HRP (Dako) or IRDye 680RD/800CW anti-mouse/rabbit (Li-Cor). Vorinostat (SAHA) (Cayman Chemical, Ann Arbor, MI), 10009929), Entinostat (MS-275) (Selleck Chemicals, Houston, TX), S1053), valproic acid (Sigma-Aldrich, P4543). MG132 (Sigma-Aldrich, c2211), Epoxomicin (Santa Cruz, sc-201298), Bortezomib (Santa Cruz, sc-217785), Nocodazole (Sigma-Aldrich, M1404).
6
In vitro and in vivo drug treatment protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For in vitro drug treatments, NB cell lines were seeded in either 96‐well, 6‐well plates or T25, T75 flasks (Corning) at densities that would reach 80‐90% confluency at the 24‐96‐h assay endpoints. Following an initial 24‐h incubation after seeding, drug treatments were made in fresh media. GSAO and PENAO were kindly provided by Prof. Philip J. Hogg (Australian Cancer Research Foundation, Centenary Cancer Research Centre, Charles Perkins Centre, USYD, NSW, Australia) and were constituted in saline (NaCl 0.9%). Vorinostat (SAHA) (#10009929, Cayman Chemical, MI) and Panobinostat (LBH589) (#13280, Cayman Chemical) were constituted in DMSO (Sigma‐Aldrich, Castle Hill, NSW, Australia). Glutathione ethyl ester (GSH‐EE) (G1404, Sigma‐Aldrich) and N‐Acetyl‐L‐Cysteine (NAC) (A9165, Sigma‐Aldrich) were constituted in Milli‐Q H2O. Cells were incubated at 37°C with 5% CO2 for 24 to 96 h, followed by various phenotypic assays.
For in vivo drug treatments, PENAO and GSAO were constituted in saline (NaCl 0.9%) prior to injection. The chemotherapy drugs; cisplatin (Hospira), vincristine (Tocris), etoposide (Sigma) and cyclophosphamide (Baxter) were diluted from their stock solution to 5% dextrose for injection. SAHA was diluted in a solution of 5% DMSO with saline (NaCl 0.9%) prior to injection.
For in vivo drug treatments, PENAO and GSAO were constituted in saline (NaCl 0.9%) prior to injection. The chemotherapy drugs; cisplatin (Hospira), vincristine (Tocris), etoposide (Sigma) and cyclophosphamide (Baxter) were diluted from their stock solution to 5% dextrose for injection. SAHA was diluted in a solution of 5% DMSO with saline (NaCl 0.9%) prior to injection.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!